Drug Trial Radar · NCT04992208
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31,041
Actual
Start
Jul 24, 2021
Primary completion
Mar 24, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated vaccine in population aged 3\~17 years and in people with pre-existing disease to provide reference for improving the immunization strategy of COVID-19 vaccine.
Conditions
- COVID-19
Interventions
Experimental GroupBiological
SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety index 1-incidence of adverse reactionsTime frame: Within 0~7 days after each dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongping Center for Diseases Control and Prevention
Dali, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.